Taro Pharmaceutical Indus Q3 2024 GAAP EPS $0.54 Beats $0.30 Estimate
Taro Pharmaceutical Indus Q3 2024 GAAP EPS $0.54 Beats $0.30 Estimate
太郎製藥工業公司2024年第三季度GAAP每股收益0.54美元，超過預期的0.30美元
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.30 by 80 percent. The company reported quarterly sales of $157.10 million which beat the analyst consensus estimate of $154.91 million by 1.42 percent. This is a 12.86 percent increase over sales of $139.20 million the same period last year.
太郎製藥工業公司（紐約證券交易所代碼：TARO）公佈的季度收益爲每股0.54美元，比分析師普遍預期的0.30美元高出80％。該公司公佈的季度銷售額爲1.571億美元，比分析師普遍預期的1.5491億美元高出1.42％。這比去年同期的1.3920億美元銷售額增長了12.86％。